Actinium Pharmaceuticals, Inc.

Listed Company

ATNMCIK 0001388320NYSENon-AcceleratedSmaller ReportingPharmaceutical PreparationsDelawareFY ends Dec 31

Period

FY 2025

Revenue

$90.0K

Net Income

$-33.89M

Total Assets

$51.77M

Equity

$7.83M

Shares Out

31.37M

Op. Cash Flow

$-24.58M

Business

Actinium Pharmaceuticals, Inc. develops targeted radiotherapies that use biologic molecules linked to radioisotopes to treat advanced and relapsed or refractory cancers. Its main product candidates include Actimab‑A (Ac‑225 CD33‑targeted therapy), Iomab‑ACT (I‑131 CD45 targeted conditioning), ATNM‑400 (Ac‑225 prostate cancer program) and the Iomab‑B program, supported by preclinical research and proprietary Ac‑225 cyclotron production. Key business areas comprise clinical development, preclinical R&D, in‑house and CDMO manufacturing, isotope production technology and strategic collaborations such as an NCI CRADA. Actinium conducts clinical trials and supplies investigational products through major cancer centers, CDMOs and clinical networks in the U.S., Canada and international markets including Europe.

Summary from filing dated 2025-03-31

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Total revenue	90,000	—	81,000	1	1
Research and development, net of reimbursements	21	30	39	23	18
General and administrative	15	12	13	12	8
Total operating expenses	36	42	52	35	26
Loss from operations	−36	−42	−52	−34	−25
Interest income net	2	4	3	—	—
Total other income	2	4	3	1	190,000
Net loss	−34	−38	−49	−33	−25
Net loss per common share basic (in Dollars per share)	−1.09	−1.27	−1.83	−1.37	−1.2
Net loss per common share diluted (in Dollars per share)	−1.09	−1.27	−1.83	−1.37	−1.2
Weighted average common shares outstanding basic (in Shares)	31	30	27	24	21
Weighted average common shares outstanding diluted (in Shares)	31	30	27	24	21

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	48	73	77	109	78
Prepaid expenses and other current assets	1	2	2	2	1
Total Current Assets	49	75	78	111	80
Property and equipment, net of accumulated depreciation of $1,064 and $891	295,000	364,000	550,000	604,000	340,000
Restricted cash long term	335,000	324,000	313,000	302,000	—
Operating lease right-of-use assets	2	2	2	2	241,000
Finance leases right-of-use assets	10,000	20,000	30,000	3,000	58,000
Total Assets	52	77	81	114	80
Accounts payable and accrued expenses	7	8	8	—	—
Operating leases current liability	711,000	569,000	530,000	494,000	245,000
Finance leases current liability	11,000	11,000	11,000	4,000	62,000
Total Current Liabilities	8	8	8	11	7
Long-term license revenue deferred	35	35	35	—	—
Long-term operating lease obligations	972,000	984,000	2	2	—
Long-term finance lease obligations	—	9,000	19,000	—	3,000
Total Liabilities	44	44	45	48	7
Commitments and contingencies	—	—	—	—	—
Preferred stock, $0.001 par value; 50,000,000 shares authorized, 0 shares issued and outstanding	—	—	—	—	—
Common stock, $0.001 par value; 1,000,000,000 shares authorized; 31,195,891 shares issued and outstanding at December 31, 2025 and 2024, respectively	31,000	31,000	28,000	26,000	22,000
Additional paid-in capital	418	409	374	355	329
Accumulated other comprehensive loss	−20,000	—	—	—	—
Accumulated deficit	−410	−376	−338	−289	−256
Total Stockholders Equity	8	33	36	66	74
Total Liabilities and Stockholders Equity	52	77	81	114	80

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Stock-based compensation expense	9	5	4	3	2
Depreciation expense	173,000	197,000	—	—	—
Amortization of right-of-use assets	648,000	614,000	583,000	—	—
Prepaid expenses and other current assets	219,000	−15,000	49,000	−158,000	−161,000
Accounts payable and accrued expenses	−346,000	−387,000	−2	5	1
Operating lease liabilities	−577,000	−530,000	−494,000	−272,000	—
Net Cash Used In Operating Activities	−25	−33	−47	9	−21
Purchase of property and equipment	−104,000	−11,000	−153,000	−366,000	−133,000
Net Cash Used In Investing Activities	−104,000	−11,000	−153,000	−366,000	−133,000
Payments on finance leases	−10,000	−9,000	−4,000	−49,000	−85,000
Proceeds from sales of shares of common stock, net of offering costs	—	29	15	23	35
Restricted stock units withheld to cover tax obligations	−207,000	—	—	—	—
Proceeds from the exercise of stock options	—	75,000	262,000	—	6,000
Net Cash (Used In) Provided By Financing Activities	−217,000	29	15	23	35
Effect of foreign currency rates on cash	6,000	—	—	—	—
Net Change in Cash, Cash Equivalents and Restricted Cash	−25	−4	—	31	14
Right-of-use assets obtained in exchange for lease liabilities	708,000	—	30,000	3	—

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro